Beyond The Patent Cliff
In 2012, drugmakers lost many key patents, but that was just a part of a broad industry transformation
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
December 10, 2012 Cover
Volume 90, Issue 50
In 2012, drugmakers lost many key patents, but that was just a part of a broad industry transformation
In 2012, drugmakers lost many key patents, but that was just a part of a broad industry transformation
Confusion over requirement leads to analysis, revision of review criteria
Some experiments find cell damage and increased risk of sexually transmitted infections
Team redesigns enzyme to stop harmful immune reactions caused by gluten-based peptides
The closure of Merck Serono’s Geneva site prompts staffers to consider launching their own firms
Chlorinated methanes are detected, but their carbon source, whether they are biological or not, is still unknown